MDAIW · Spectral AI, Inc.
Price & Indicators
The closing range uses available history since Jul 23, 2026; less than a full year is stored.
Up next
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -5.25M | Six Months Ended June 30, 2026 | — |
| EBITDA non-GAAP | -6.55M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDAIW
this stock
Spectral AI, Inc.
|
$46.35M | — | -33.6% | — | — |
|
ABT
Abbott Laboratories
|
$180.00B | -17.2% | +5.7% | 33.4 | 0.8% |
|
MDT
Medtronic plc
|
$122.04B | -0.7% | +8.4% | 23.5 | 3.1% |
|
SYK
Stryker Corp
|
$117.87B | -12.6% | +11.2% | 31.8 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.22B | -52.1% | +12.5% | 18.5 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 21.6%
- Reported
- 3 of 52
- Top holder
- VANGUARD CAPITAL MANAGEME…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDAIW | +0.2% | -0.9% | — | -5.2% | — |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | +0.6% | +0.6% | — | -4.8% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.